Sai Parenterals Secures Rs 50 Crore for Global Expansion and Manufacturing Boost
Sai Parenterals Limited has secured Rs 50 crore in funding, led by prominent investors including Samarsh Capital, Vyom Partners, and Blue Lotus Capital. The company aims to use these funds to expand its global footprint and enhance its manufacturing capabilities.
Based in India, Sai Parenterals operates five facilities, with some approved by international regulatory bodies such as TGA Australia, GCC, SAPRA, and WHO GMP. The company offers a wide range of products, including injectables, oral solids and liquids, and topical preparations, and operates across the pharmaceutical value chain.
Anil Karusala, Managing Director of Sai Parenterals, envisions building a global pharmaceutical company with high standards and practices. The company has two strategic business verticals: Branded Export Formulations and Contract Development & Manufacturing Organization (CDMO) Services. With the recent funding, Sai Parenterals plans to acquire international assets and intellectual property, expand its product portfolio and geographical presence, and enhance its manufacturing capabilities.
The funding round was led by marquee investors, with Blue Lotus Capital's Managing Partner, Harikrishnan S, expressing confidence in Sai Parenterals' science-driven culture and manufacturing platform. With the new funds, Sai Parenterals is poised to accelerate its growth and establish a strong international presence.
Read also:
- Is it advisable to utilize your personal health insurance in a publicly-funded medical facility?
- Dietary strategies for IBS elimination: Aims and execution methods
- Benefits, suitable dosage, and safety considerations for utilizing pumpkin seed oil in treating an overactive bladder
- Harmful Medical Remedies: A Misguided Approach to Healing
